JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

37.95 2.51

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

36.41

Max

38.18

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	11.937 84.243
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+28.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	492M 2.2B
Ankstesnė atidarymo kaina	35.44
Ankstesnė uždarymo kaina	37.95

Naujienos nuotaikos

By Acuity

34%

66%

80 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-09 17:25; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

2026-02-09 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

2026-02-09 23:43; UTC

Rinkos pokalbiai

Gold Falls on Possible Technical Correction -- Market Talk

2026-02-09 23:14; UTC

Rinkos pokalbiai

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

2026-02-09 22:29; UTC

Rinkos pokalbiai

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

2026-02-09 22:19; UTC

Rinkos pokalbiai

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

2026-02-09 22:08; UTC

Rinkos pokalbiai

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

2026-02-09 22:01; UTC

Uždarbis

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

2026-02-09 21:59; UTC

Uždarbis

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

2026-02-09 21:59; UTC

Uždarbis

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

2026-02-09 21:58; UTC

Uždarbis

Friedman Industries 3Q Sales $168M >FRD

2026-02-09 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-09 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-09 21:48; UTC

Uždarbis

Friedman Industries 3Q EPS 43c >FRD

2026-02-09 21:17; UTC

Uždarbis

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

2026-02-09 21:13; UTC

Rinkos pokalbiai

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

2026-02-09 21:04; UTC

Uždarbis

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

2026-02-09 20:30; UTC

Rinkos pokalbiai

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

2026-02-09 20:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

2026-02-09 19:42; UTC

Rinkos pokalbiai

Japan's Yield Curve Expected to Flatten -- Market Talk

2026-02-09 19:31; UTC

Rinkos pokalbiai

Nike Seen Regaining Relevance With Consumers -- Market Talk

2026-02-09 19:27; UTC

Rinkos pokalbiai

Gold Climbs Back Over $5,000/oz -- Market Talk

2026-02-09 19:05; UTC

Rinkos pokalbiai

Nike Returns to List of Hottest Brands -- Market Talk

2026-02-09 18:19; UTC

Rinkos pokalbiai

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

2026-02-09 17:41; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

2026-02-09 17:31; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

2026-02-09 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-09 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-09 17:17; UTC

Rinkos pokalbiai

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

2026-02-09 17:16; UTC

Uždarbis

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

28.56% į viršų

12 mėnesių prognozė

Vidutinis 47.67 USD 28.56%

Aukščiausias 55 USD

Žemiausias 42 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

80 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.